Current Turnaround: 24-Hours
PCL makes gastrointestinal testing simple by only requiring a small amount of specimen. By utilizing molecular technology, PCL can accurately identify GI infections using a simple swab to collect a small amount of material from a sample. This process makes it easier and safer for the collector and more convenient for the patient.
H. pylori Testing
Our fecal swab can also test for H. pylori, making it easier to ship than breath tests, and makes collection simple, especially for children who have trouble providing enough sample to fill a bag. Typical blood tests for H. pylori may still show positive after treatment due to antibodies, however, Patients Choice fecal swab prevents this false-positive.
Fast Track Treatments
Patients Choice GI+ test delivers advanced DNA analysis using Real-Time PCR technology, providing absolute identification of microorganisms within 24-hours. The GI+ test provides insight into microorganisms contributing to polymicrobial infection, quantification, and resistance gene identification with custom treatment recommendations leading to increased patient outcomes and lower healthcare costs.
This State-of-the-art technology and Antimicrobial Stewardship Program aims to improve the effectiveness of antimicrobial treatment and patient outcomes by proving physicians with the tools they need to optimize the use of advanced diagnostics.
Patients Choice Advantage
Results within 24-hours from when the sample arrives at the lab.
Changes the way infections are diagnosed and treated by identifying microbes by their DNA.
Molecular technology can find and identify polymicrobial infections.
Faster more accurate results, allowing physicians to act sooner and with more precision than ever.
Identification of resistant genes so that targeted therapy can be implemented from the onset of diagnosis.
Ability to detect bacterial and fungal microbes, many that are viable-but-nonculturable.
Estimated cases of
hospitalized patients in 2017
Estimated deaths in 2017
healthcare costs in 2017
A common strain of C. diff (ribotype 027) that can cause more serious disease can be associated with the use of certain antibiotics, such as fluoroquinolones. Improving antibiotic use is an important strategy to reduce these infections as antibiotics disrupt our microbiome.6
The most common places Norovirus outbreaks are reported is in healthcare facilities, including long-term care facilities and hospitals. Outbreaks in these settings can sometimes last months and be more severe, occasionally even deadly, when compared with healthy people.1
3 out of 4 norovirus outbreaks
occur in US long-term care facilities.1
H. pylori is present in approximately 50% of the world’s population and studies have shown that H. pylori is the primary cause of gastric (stomach) cancer, a type of cancer caused by infectious agents that could be prevented by treating the infection.2
26,000 estimated new cases of
gastric cancer in 2022.3
C. diff is estimated to cause almost half a million infections in the US each year and is now among the most common causes of hospital and long-term care acquired infections. The risk of recurrence after an initial episode of CDI is 20% and increased up to 60% after the third episode.4,5
1 in 11 people over the age 65 with healthcare-associated C. diff die within one-month.4
1. https://www.cdc.gov/norovirus/trends-outbreaks/outbreaks.html 2. Holleczek B, Schottker B, Brenner H. Helicobacter pylori infection, chronic atrophic gastritis and risk of stomach and esophagus cancer: Results from the prospective population-based ESTHER cohort study. Int J Cancer. 2020;146: 2773-2783. 3. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2022/2022-cancer-facts-and-figures.pdf 4. https://www.cdc.gov/cdiff/what-is.html 5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3903088/ 6. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf